Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 12, Issue 10, Pages 1275-1287Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.12.10.1275
Keywords
Alzheimer's disease; cancer; cancer metastasis; GPCR; MAPK; NF-kappa B; PEBP; RKIP
Categories
Funding
- National Institutes of Health [NS33858, CA112310]
- University of Chicago Cancer Research Center
- Cornelius Crane Trust for Eczema Research
- NATIONAL CANCER INSTITUTE [R01CA112310] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033858] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Background: Raf kinase inhibitory protein (RKIP) belongs to the phosphaticlylethanolamine binding protein (PEBP) family that is expressed in both prokaryotic and euakaryotic organisms. Objective: In this review, we discuss the role of RKIP as a modulator of signal transduction, the relationship of RKIP to other members of the PEBP family, and the role of RKIP in human health and disease. Results/conclusion: In mammals, RKIP regulates activation of MAPK, NF-kappa B and G protein coupled receptors (GPCRs). As a modulator of key signaling pathways, RKIP affects various cellular processes including cell differentiation, the cell cycle, apoptosis and cell migration. Emerging evidence suggests that RKIP is implicated in several human diseases or disorders, among them metastatic tumorigenesis and Alzheimer's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
